-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
Naloxone hydrochloride is an opioid receptor antagonist.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
.
.
Data source: Mi Neiwang database, NMPA
Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
Naloxone hydrochloride is an opioid receptor antagonist.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
.
.
Data source: Mi Neiwang database, NMPA
Medical Network News, August 18, August 16, NMPA official website showed that Yuandong Bio's naloxone hydrochloride injection passed the consistency evaluation and was the first company to pass the evaluation
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
.
Naloxone hydrochloride is an opioid receptor antagonist, and its terminal sales in China's public medical institutions will exceed 700 million yuan in 2020
.
Up to now, 16 varieties of Yuandong Biology have been evaluated (5 are the first ones)
.
Naloxone hydrochloride is an opioid receptor antagonist.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
It is suitable for acute poisoning of narcotic analgesics and acute alcohol poisoning.
It is also used for respiratory depression and coma caused by known or suspected opioid overdose.
It can also be used for opioids.
Differential diagnosis of drug addicts
.
Meinenet data shows that in 2020, China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal sales of naloxone exceed 700 million yuan
.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
Hospital Hospital Hospital Enterprise Enterprise Enterprise.
Among them, Chenxin Pharmaceutical, Yuandong Biological, Chengdu Tiantaishan Pharmaceutical and other three companies have a market share of more than 15%
.
Sales of terminal naloxone in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, there are 24 manufacturers of naloxone hydrochloride injection in the domestic market, but only Yuandong Biotech has submitted a supplementary application for consistency evaluation
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
.
In addition, Sichuan Meida Kangjiale Pharmaceutical has exclusively submitted an application for the marketing of naloxone hydrochloride injection with imitation 3 types.
If it is successfully approved, it will be deemed to have been reviewed
.
Up to now, Yuandong Biology has 16 varieties (31 product specifications) passed/deemed to pass the consistency evaluation, of which 5 varieties are the first to pass the evaluation
.
.
Data source: Mi Neiwang database, NMPA